Sure enough, the news that Rachel Wang said next made the expression on Ye Leiyang's face become strange. Pen? Interesting? Pavilion wWw. ｂiquge。 ｉｎfo

"My senior, has made progress in research recently, but the problem is that the company that originally supported the funds of his research group has gone bankrupt, and the research group is about to be disbanded, he is very anxious, and he heard that I am making investments, so he found me."

When Rachel Wang spoke, he glanced at Ye Leiyang cautiously, for fear that he would misunderstand that he was pretending to help his acquaintances, after all, no matter what, although the relationship between himself and Tian Xiaoxu is there, as a person who has watched Ye Leiyang step by step to this day, Wang Rachel knows very well that this brother-in-law does not look at the stoic and low-key appearance in China, but his family background abroad is quite rich. And in the United States, having money means having everything.

Ye Leiyang smiled, he could vaguely guess Wang Rachel's thoughts, but this is fine, if people are not in awe, then they will be unscrupulous, rather than turning against each other at that time, it is better to set the rules now.

After all, many things in life, many circumstances, and even many people, we are actually more satisfied with the first time we met, because the beauty between each other was still there at that time, but as time went by, looking back, it was still a matter of people, vicissitudes.

Maybe it's a bit impersonal to do this, but there are not so many people in the world who are more heart-to-heart and blindly give, just those who are used to getting in.

If a person thinks too much about the feelings of others, he is destined to feel bad in the end.

Ye Leiyang's idea is very simple, be loyal to your heart and live comfortably.

"What is your classmate's research about?" Ye Leiyang looked at Wang Rachel and asked.

This thing Wang Rachel said, whether it is true or not, he has to find someone to evaluate it, after all, this kind of investment is not 120,000 US dollars, but tens of millions or even more investment, which is real money.

Hearing Ye Leiyang's words, Wang Rachel was overjoyed, since Ye Leiyang asked himself, it showed that he was interested in this matter, no matter what the final result was, whether he would invest or not, he could be worthy of his old classmates.

"What they're working on is an androgen receptor inhibitor for the treatment of patients with metastatic castration-tolerant prostate cancer who have been previously treated with docetaxi." Rachel Wang explained: "Mechanism of actionEnzalutamide is an androgen receptor inhibitor that acts at different steps of the androgen receptor signaling pathway. Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors and inhibit androgen receptor nuclear translocation and interaction with DNA. One major metabolite, N-desmethyl enzalutamide, exhibits in vitro activity similar to enzalutamide. Enzalutamide reduces proliferation and induces cell death in prostate cancer cells in vitro, and tumor volume reduction in a mouse prostate cancer xenograft model. ”

He said a lot of things, and Ye Leiyang said that he fainted instantly.

But Ye Leiyang still keenly noticed a few key words, and asked sharply: "You mean, if this thing is successfully developed, it can treat prostate cancer?" ”

Rachel Wang was stunned for a moment, and then nodded: "That's right, that's what it means." ”

He said so many things, and the rest was actually just explaining the front, and the question that Ye Leiyang raised now is the most critical.

Because no matter what theory a drug is based on, the ultimate goal is to treat the disease, to put it bluntly, if the disease cannot be cured and the patent right cannot be converted into wealth, then why should investors waste a lot of money on such research?

Maybe someone is a philanthropist and likes to be a good person, but it is obvious that Ye Leiyang is not.

“enzalutamide？” An English word suddenly popped out of Ye Leiyang's mouth, but it made Wang Rachel stunned.

"Yezi, you know this substance too?" Wang Rachel asked Ye Leiyang in surprise.

Ye Leiyang smiled, a strange smile appeared on his face, shook his head and said: "How do I know, it was you who just said, in your words just now, this word appeared many times, I think it should be some kind of substance, right?" ”

Rachel Wang nodded: "This is the substance that my seniors are studying, I think it's ......"

He began to introduce the senior's research project again, and it was clear that Rachel Wang was particularly interested in this.

Ye Leiyang listened to Wang Rachel's words with a smile on his face, but deep down there were monstrous waves in his heart!

If I remember correctly, enzalutamide capsules should be the final result of this research project.

The reason why I know this name is because Ye Leiyang once had a meal with a boss from Hong Kong in his last life, and his wife was taking this medicine, and at that time, there was another person's relatives at the dinner table who also suffered from breast cancer, and the boss talked about this medicine, saying that the effect was good, but it was a little more expensive.

Patients who take this medicine spend about 65,000 Hong Kong dollars a month, which is equivalent to nearly 56,000 yuan.

In other words, just taking this medicine a year will cost six or seven hundred thousand.

Definitely a huge profit!

This was the thought that flashed in Ye Leiyang's mind, but he never thought that this big pie could fall on him.

Ye Leiyang remembers that he once saw on the news that after entering the new millennium, the world's large pharmaceutical companies are staring at the nascent drug companies like hungry wolves, and most of these pharmaceutical companies have one or two mature drugs in the latest biopharmaceutical, immunotherapy and other fields, and product pipelines in the second and third experimental stages, which are also favored by the capital market.

Behind the frenzy of leading pharmaceutical giants to grab small and medium-sized pharmaceutical companies is the anxiety of traditional pharmaceutical companies about the future: existing mature drugs will lose patent protection in large numbers in the next few years, and new drugs are still under development. In addition, most of the pharmaceutical giants have a long history, and in the face of today's biopharmaceutical trends, the talent team also feels powerless.

Originally, Ye Leiyang did not plan to enter this industry, not only because of the high investment and long cycle of this industry, but also because he was not sure which research would be able to get a return.

This is the truth, drug research and development requires a lot of capital investment, sometimes even hundreds of millions of dollars plus several years of time to invest, but in the end, it is empty, so Ye Leiyang would rather choose a more complex industrial investment than get involved in the drug research and development industry.

It's just that he never thought that the big cake of enzalutamide would one day fall on his head.

For a while, even Ye Leiyang himself felt a little like in a dream. (To be continued.) )